Get the latest news, insights, and market updates on BIIB (Biogen Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call
Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales. Management attributed performance to robust growth in its newer product portfolio, particularly Lekembi, Skyclaris, Xerxuve, and Calcadi, which collectively surpassed $1 billion in annual revenue. CEO Christopher Viehbacher pointed to successful expansion of VUMERITY within the multiple sclerosis segment Feb 13, 2026 - $BIIB
1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory. Feb 13, 2026 - $BIIB
Biogen Announces Board Chair Transition
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new ChairCAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Board of Directors has elected Dr. Maria C. Freire as Chair of the Board of Directors, effective immediately following the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to take place on June 9, 2026. Dr. Freire will succeed Caroline Dorsa Feb 11, 2026 - $BIIB
Why Biogen (BIIB) Is Up 8.2% After Mixed 2025 Earnings and Neurology Pipeline Updates – And What's Next
Biogen recently reported fourth-quarter and full-year 2025 results showing quarterly sales of US$521.2 million and revenue of US$2.28 billion, but a quarterly net loss of US$48.9 million contrasted with a strong full-year net income of US$1.29 billion. Alongside earnings, Biogen highlighted progress in its neurology pipeline, including FDA Breakthrough Therapy Designation for litifilimab in cutaneous lupus and ongoing review of a high-dose SPINRAZA regimen for spinal muscular atrophy. Next,... Feb 10, 2026 - $BIIB
Biogen Pipeline Advances In Lupus And SMA Reshape Growth Outlook
Biogen (NasdaqGS:BIIB) received Breakthrough Therapy Designation from the FDA for litifilimab in cutaneous lupus erythematosus. The company reported phase 2/3 trial results for high dose nusinersen in spinal muscular atrophy. Both updates relate to Biogen's drug pipeline in neurological and autoimmune diseases. For investors watching Biogen, these updates go to the heart of what drives the company: its drug pipeline. Biogen is known for treatments targeting neurological and related... Feb 10, 2026 - $BIIB
Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump
Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer's drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis. Drugs Performance Biogen on Friday said fiscal 2025 revenue from growth products increased 19% year-over-year and offset the year-over-year revenue decline from multiple sclerosis products, exclu Feb 8, 2026 - $BIIB
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple